Lemtrada Fears May Be Overdone

Lemtrada Stroke Lawsuit News

Regulators may have scared potential Lemtrada patients away when highlighting the risks of stroke and heart attack patients could suffer

Thursday, January 30, 2020 - Relapse-remitting multiple sclerosis (RRMS) patients today must understand the risks of the drug and balance them against the many benefits the drug can offer. RRMS patient report having intermittent attacks followed by periods of remission. Lemtrada patients sometimes rave about the long-term benefits the drug has afforded them for preventing or delaying the progression of their disease. Multiple Sclerosis News Today (MSNT) reported the results of a study called "Alemtuzumab CARE-MS I 5-year follow-up" of Lemtrada patients over five years and found that the drug is highly effective. The study also pointed out that few people developed new brain lesions that required a double dose of the treatments. MSNT reports that 96% of the 367 patients in the study remained relapse-free for the full five years. Over 80% of the study's participants "were free from six-month confirmed disability worsening, and about one-third had six-month confirmed disability improvement." Most patients showed no signs of the disease after about 3 years. Adverse side effects from Lemtrada treatments were limited to headaches, fever, and rashes. Lemtrada stroke lawsuits are represented by top national attorneys with vast experience litigating pharmaceutical lawsuits and offer a no obligation free consultation.

Lemtrada is considered a drug of last resort in the treatment of relapse-remitting multiple sclerosis (RRMS). The disease first occurs in young men and women in their late 20's and early 30's beginning with numbness in the legs or arms. The disease progresses to active periods called flare-ups where a patient experiences the loss of control of the limbs and eventually the inability to get out of bed. The disease goes into remission periods that can last months or more. In addition to numbness and tingling in the extremities, blurry vision and jumpy eyes can be early warning signs that you may have the disease. Lemtrada can only be given to patients after two or more alternative drugs have failed. The drug carries the risk of causing an immediate stroke within 24-hours of receiving a treatment which consists of six sessions over two weeks. It is only recently that the maker of Lemtrada, Sanofi, acknowledged and warned patients of these potentially life-threatening risks. Patients that have been injured by the drug have consulted with Lemtrada stroke attorneys to see if they qualify to file a claim against the drug's maker. Lemtrada patients have reported serious, life-threatening side effects including irreversible paralysis from having a stroke and immediate death from a heart attack. Lemtrada causes tears in the arterial lining of the head and neck leading to stroke and brain bleeding. Lemtrada strokes can also result in permanent brain damage.

Lemtrada, (alemtuzumab) is a monoclonal antibody that works by attaching to the CD52 protein in white blood cells, the building blocks of the human immune system, and kills them, causing them to be replaced with new healthy cells. Lemtrada treatments are infusion IV drips performed annually in a two-day session. Lemtrada mitigates the intensity of the RRMS lapses and extends the remission. Lemtrada patients pay a price for the drug's effectiveness as it is considered one of the most dangerous on the market. Doctors that administer the drug must do so in a hospital with an emergency room available.

More Recent Lemtrada Stroke Lawsuit News:

No-Cost, No-Obligation Lemtrada Lawsuit Case Review If You or a Loved One Suffered from Lemtrada Stroke Complications

OnderLaw, LLC is a St. Louis personal injury law firm handling serious injury and death claims across the country. Its mission is the pursuit of justice, no matter how complex the case or strenuous the effort. The Onder Law Firm has represented clients throughout the United States in pharmaceutical and medical device litigation such as Pradaxa, Lexapro and Yasmin/Yaz, where the firm's attorneys held significant leadership roles in the litigation, as well as Actos, DePuy, Risperdal and others. The Onder Law Firm has won more than $300 million in four talcum powder ovarian cancer lawsuits in St. Louis. Law firms throughout the nation often seek its experience and expertise on complex litigation.